Stock Analysis
- China
- /
- Electronic Equipment and Components
- /
- SHSE:688320
3 Growth Companies With High Insider Ownership And 22% Revenue Growth
Reviewed by Simply Wall St
In recent weeks, global markets have shown varied performances, with the S&P 500 Index advancing and small-cap indices like the Russell 2000 outperforming, while European markets reacted positively to interest rate cuts by the ECB. Amid these developments, investors are increasingly interested in growth companies with high insider ownership as they often indicate strong confidence from those closest to the business. In this context, identifying stocks that not only demonstrate robust revenue growth but also feature significant insider stakes can be a promising strategy for navigating current market conditions.
Top 10 Growth Companies With High Insider Ownership
Name | Insider Ownership | Earnings Growth |
Lavvi Empreendimentos Imobiliários (BOVESPA:LAVV3) | 11.9% | 21.1% |
Archean Chemical Industries (NSEI:ACI) | 22.9% | 34% |
Kirloskar Pneumatic (BSE:505283) | 30.3% | 30.1% |
People & Technology (KOSDAQ:A137400) | 16.4% | 35.6% |
Arctech Solar Holding (SHSE:688408) | 37.8% | 29.8% |
Seojin SystemLtd (KOSDAQ:A178320) | 30.7% | 49.1% |
Medley (TSE:4480) | 34% | 30.4% |
HANA Micron (KOSDAQ:A067310) | 18.3% | 105.8% |
Adveritas (ASX:AV1) | 21.2% | 144.2% |
Plenti Group (ASX:PLT) | 12.8% | 106.4% |
Let's review some notable picks from our screened stocks.
Chengdu Olymvax Biopharmaceuticals (SHSE:688319)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Chengdu Olymvax Biopharmaceuticals Inc. is involved in the research, development, production, and sale of human vaccines with a market cap of CN¥44.00 billion.
Operations: The company's revenue primarily comes from its Medicine Manufacturing segment, which generated CN¥489.20 million.
Insider Ownership: 24.5%
Revenue Growth Forecast: 22.4% p.a.
Chengdu Olymvax Biopharmaceuticals is forecast to grow revenue by 22.4% annually, outpacing the Chinese market's growth rate of 13.5%. Despite a recent net loss of CNY 27.95 million for the half-year ending June 2024, it is expected to become profitable within three years. The stock trades at a significant discount to its estimated fair value, though its return on equity is projected to remain modest at 9.7%.
- Click here and access our complete growth analysis report to understand the dynamics of Chengdu Olymvax Biopharmaceuticals.
- The valuation report we've compiled suggests that Chengdu Olymvax Biopharmaceuticals' current price could be inflated.
Zhejiang Hechuan Technology (SHSE:688320)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Zhejiang Hechuan Technology Co., Ltd. focuses on the research, development, manufacturing, sale, and application integration of industrial automation products, with a market cap of CN¥4.45 billion.
Operations: I'm sorry, but it seems there is no specific information provided about the revenue segments for Zhejiang Hechuan Technology Co., Ltd.
Insider Ownership: 30.8%
Revenue Growth Forecast: 14.4% p.a.
Zhejiang Hechuan Technology is projected to achieve profitability within three years, with revenue growth anticipated at 14.4% annually, surpassing the broader Chinese market's pace of 13.5%. Despite a net loss of CNY 29.19 million for the half-year ending June 2024, insider ownership remains strong with no significant insider trading activity recently. The company completed a share buyback worth CNY 62.13 million, reflecting management's confidence amidst recent volatility in share price.
- Click here to discover the nuances of Zhejiang Hechuan Technology with our detailed analytical future growth report.
- Our valuation report unveils the possibility Zhejiang Hechuan Technology's shares may be trading at a premium.
Fujian Boss Software (SZSE:300525)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Fujian Boss Software Corp. provides software products and services in China, with a market capitalization of CN¥12.28 billion.
Operations: The company generates revenue through its software products and services within China.
Insider Ownership: 26.7%
Revenue Growth Forecast: 20.7% p.a.
Fujian Boss Software demonstrates strong insider ownership with no significant insider trading activity recently. The company reported a net loss of CNY 37.72 million for the first half of 2024, yet revenue grew to CNY 717.4 million from the previous year. Despite an unstable dividend track record, it completed a share buyback worth CNY 77.36 million, indicating management's confidence. Revenue is forecasted to grow at 20.7% annually, outpacing the broader Chinese market growth rate.
- Unlock comprehensive insights into our analysis of Fujian Boss Software stock in this growth report.
- Our valuation report here indicates Fujian Boss Software may be undervalued.
Key Takeaways
- Navigate through the entire inventory of 1485 Fast Growing Companies With High Insider Ownership here.
- Invested in any of these stocks? Simplify your portfolio management with Simply Wall St and stay ahead with our alerts for any critical updates on your stocks.
- Simply Wall St is your key to unlocking global market trends, a free user-friendly app for forward-thinking investors.
Interested In Other Possibilities?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Valuation is complex, but we're here to simplify it.
Discover if Zhejiang Hechuan Technology might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About SHSE:688320
Zhejiang Hechuan Technology
Engages in the research and development, manufacturing, sale, and application integration of industrial automation products.